Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miranda, A.
Right arrow Articles by Verspaget, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miranda, A.
Right arrow Articles by Verspaget, H. W.
Clinical Cancer Research Vol. 6, 3183-3192, August 2000
© 2000 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Superoxide Dismutases in Gastric and Esophageal Cancer and the Prognostic Impact in Gastric Cancer1

A. Miranda, L. Janssen, Coen B. Bosman, Wim van Duijn, Marjan M. Oostendorp-van de Ruit, Frank J. G. M. Kubben, Gerrit Griffioen, Cornelis B. H. W. Lamers, J. Han, J. M. van Krieken, Cornelis J. H. van de Velde and Hein W. Verspaget2

Departments of Gastroenterology and Hepatology [A. M. L. J., C. B. B., W. v. D., M. M. O-v. d. R., F. J. G. M. K., G. G., C. B. H. W. L., H. W. V.], Pathology [J. H. J. M. v. K.], and Oncologic Surgery [C. J. H. v. d. V.], Leiden University Medical Center, 2300 RC Leiden, the Netherlands


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The oxidant-antioxidant balance is thought to be important in the initiation, promotion, and therapy resistance of cancer. In the present study, we assessed the expression of the antioxidants manganese superoxide dismutase (Mn-SOD) and copper/zinc superoxide dismutase in gastric and esophageal carcinomas and their relation with clinical outcome. Adenocarcinomas of the stomach (n = 81) as well as squamous cell carcinomas of the esophagus (n = 10) showed an enhanced immunohistochemical expression of Mn-SOD, which was accompanied by a significantly higher tissue level (P <= 0.007) compared with their corresponding normal mucosa. In contrast, copper/zinc superoxide dismutase was found to be marginally lower in these malignant tissues in comparison with the normal tissues. The superoxide dismutase levels were not found to be associated with major clinicopathological features of the gastric cancer patients. Univariate analysis revealed, however, that a high Mn-SOD level in gastric carcinomas, a low level in the normal gastric mucosa, and a high ratio of these two levels in gastric cancer patients are indicative of a poor overall survival. Multivariate analysis, including all clinicopathological parameters, revealed that the Mn-SOD ratio in particular is an independent prognostic parameter in gastric cancer patients. Although the mechanism(s) that up-regulate Mn-SOD in gastric and esophageal cancer, which is also thought to confer therapy resistance, are not yet fully elucidated, it seems to be clinically relevant for patients’ survival, similar to that as previously reported for colorectal cancer.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The antioxidant enzyme SOD,3 in combination with enzymes like myeloperoxidase, catalase, and glutathione peroxidase, forms the backbone of the primary cellular defense mechanism against ROMs (1, 2, 3, 4) . These ROMs, including true free radicals, such as superoxide anion (O2) and hydroxyl radical (OH·), as well as nonradical compounds, such as hydrogen peroxide (H2O2), are continuously produced during aerobic metabolism (5) . Under normal conditions, cells are protected against the toxic effects of high concentrations of ROMs by a balanced level of endogenous enzymatic and nonenzymatic antioxidants. However, oxidative damage can arise either from the overproduction of ROMs or from an imbalance of antioxidant defense mechanisms, and it has been implicated in the development and treatment of diseases such as cancer (3 , 5, 6, 7, 8, 9, 10, 11, 12, 13, 14) .

The antioxidant enzyme SOD catalyzes the dismutation of O2 to H2O2, thereby preventing the accumulation of this free radical. Subsequently, H2O2 can be converted into H2O and O2 by catalase and/or glutathione peroxidase (1, 2, 3, 4 , 9) . In human tissues, there are at least three different SOD enzymes. These include a cytoplasmic Cu/Zn-SOD, a mitochondrial Mn-SOD, and an extracellularly localized SOD (1 , 2 , 4 , 9 , 15) . We recently showed that human colorectal cancer development is associated with a significant increase in Mn-SOD, whereas no major differences were found with regard to Cu/Zn-SOD (16) . In a larger study, the increased Mn-SOD antigen level of colorectal carcinomas was found to be an independent prognostic factor for the overall survival of the patients (17) . Recently, Izutani et al. (18 , 19) reported that cancers of the upper gastrointestinal tract are also characterized by an increased expression of Mn-SOD.

In the present study, we investigated SODs in gastrointestinal cancer further by evaluating 81 patients with gastric cancer and 10 patients with esophageal cancer. With respect to the gastric cancer patients, the relationship with several clinicopathological parameters and the prognostic value of the SOD content for the overall survival of the patients were determined as well.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients and Study Design.
Fresh tissue could be prospectively collected from 81 consecutive patients (21 females and 60 males; mean age, 65.9 ± 1.4 years) who underwent resection for primary gastric cancer (adenocarcinoma) and from 10 patients (8 females and 2 males; mean age, 57.6 ± 3.5 years) who were operated on for primary squamous cell carcinoma of the esophagus at the Department of Oncological Surgery. Immediately after resection, the specimens were transported to the Department of Pathology, and samples of carcinomas and macroscopically normal mucosa, taken ~5–10 cm from the tumor, were snap-frozen and stored at -70°C until extraction, when available for research purposes. Immediately adjacent tissues were used for histological reconfirmation of disease and tissue type, and for immunohistology. From the group of gastric cancer patients, several major clinical and pathological data were evaluated and registered or retrieved from their data files. Macroscopic pathological features of the gastric carcinomas, such as localization and diameter of the tumor, were assessed, and all tumors were histologically classified according to the TNM classification (20) . Microscopic histological parameters, such as the WHO and Laurén (21) classification, the number of eosinophils, as well as the presence of intestinal metaplasia in the normal mucosa, were revised by one pathologist. With regard to the survival analyses of the gastric cancer patients, all patients entered the study at operation date, and the patients’ time experience ended in the event of death or, when still alive, at the common closing date, with a minimal follow-up of 33 months.

Tissue Extraction and Protein Concentration.
Extractions were prepared from 50 to 100 mg of wet tissue samples, as described previously (22) . The samples were weighed, and 1 ml of 0.1 M Tris-HCl (pH 7.5) with 0.1% (v/v) Tween 80/60 mg of sample was added. The tissue was homogenized for 2 min on ice in a Potter S (B Braun). The homogenates were centrifuged twice at 8000 x g for 2.5 min, 4°C, and the final supernatants were stored at -70°C. The protein concentration of the supernatants was determined using the method of Lowry et al. (23) .

SOD Standards and Antibodies.
The standards used were hr Mn-SOD and Cu/Zn-SOD, kindly provided by Dr. Z. Yavin from the Kyriat Weizmann Institute (Rehovot, Israel). The monospecific antibodies raised in rabbits showed no cross-reactivity between the two SOD isoforms (Mn versus Cu/Zn) and provided no signal with other proteins of tissue homogenates on Western blotting, as reported earlier (16 , 24) .

ELISA for Cu/Zn-SOD.
The Cu/Zn-SOD antigen concentration of the tissue homogenates was determined by a modified ELISA, as described previously (16 , 24) . In brief, flat-bottomed polystyrene microtiter plates (Dynatech Laboratories; M129A) were coated with goat-{alpha}-human Cu/Zn-SOD [10 µg/ml in 0.05 M carbonate buffer (pH 9.6)] overnight at 4°C. Homogenates, diluted 1:600 in duplicate, were incubated for 2 h, and subsequently, rabbit-{alpha}-(hr) Cu/Zn-SOD polyclonal antiserum (dilution, 1:2500) was added to the wells and incubated for 1 h. Finally, a polyclonal goat-{alpha}-rabbit IgG conjugated to horseradish peroxidase (Dakopatts; P448; dilution, 1:5000) was added for 1 h, and the plates were colored with orthophenylenediamine for 30 min. The reaction was terminated with sulfuric acid, and the absorbance was read at 492 nm on a Titertek Multiscan (Flow Laboratories, Irvine, United Kingdom) plate reader. The Cu/Zn-SOD concentration of the samples was calculated from a calibration curve based on nine standards between 1.25 and 30 ng/ml (hr) Cu/Zn-SOD and expressed per mg of protein of the homogenate. The intra- and interassay coefficients of variation of this ELISA were 4 and 6%, respectively.

ELISA for Mn-SOD.
This ELISA is similar to that for Cu/Zn-SOD, as described before (16 , 24) . The microtiter plates were coated overnight at 4°C with a rabbit-{alpha}-(hr) Mn-SOD polyclonal antibody, and the homogenates were diluted 1:150. The standard line of (hr) Mn-SOD ranged from 1.25 to 40 ng/ml. After duplicate incubation with the tissue homogenates, the plates were incubated for 90 min with rabbit-{alpha}-(hr) Mn-SOD coupled to horseradish peroxidase (dilution, 1:250). Bound antibodies were detected as described for Cu/Zn-SOD. The intra- and interassay coefficients of variation of this ELISA were 5 and 10%, respectively.

SOD Enzyme Activity Assay.
The SOD activity was determined by the xanthine/xanthine-oxidase/cytochrome c method according to McCord and Fridovich (1) , as described previously (16 , 24) . Xanthine/xanthine-oxidase-produced O2 reduces cytochrome c, which can be assessed spectrophotometrically at 550 nm. SOD competes with cytochrome c for the dismutation of O2, and total SOD activity was determined in the homogenates using a calibration curve from 1.25 to 12.5 µg/ml (hr) SOD. Mn-SOD activity was determined in the presence of 1 mM sodium cyanide, which inhibits Cu/Zn-SOD for >=90%, and Cu/Zn-SOD was estimated by subtraction of the Mn-SOD from the total SOD activity. The activity is expressed in units/mg of protein, where one unit is equivalent to the SOD activity that causes 50% inhibition of the reaction rate in the absence of SOD. For Cu/Zn-SOD, one unit corresponds with 180 ng of active (hr) Cu/Zn-SOD, whereas one unit of Mn-SOD corresponds with 225 ng of active (hr) Mn-SOD.

Immunohistochemistry.
Immunolocalization of Cu/Zn-SOD and Mn-SOD was performed by an indirect peroxidase-labeled antibody method with our polyclonal rabbit antibodies, as extensively described and validated previously (16) , on 14 gastric and 10 esophageal carcinoma-normal mucosa pairs. Formalin-fixed, paraffin-embedded tissue samples were sectioned (4 µm), mounted on poly-L-lysine-coated glass slides, air-dried, deparaffinized, and rehydrated. Slides were subsequently submerged in 10 mM sodium citrate buffer (pH 6.0) and microwave-heated at 780 W for three 4-min intervals for antigen retrieval. The sections were incubated for 20 min in 5% normal goat serum to block nonspecific binding and then overnight at 4°C with rabbit-{alpha}-(hr) Cu/Zn-SOD (1:1000 dilution) or rabbit-{alpha}-(hr) Mn-SOD (1:250 dilution) polyclonal antiserum, diluted in TBS [50 mM Tris, 150 mM NaCl (pH 7.5)] containing 0.5% BSA. The sections were subsequently rinsed thoroughly, and biotinylated goat-{alpha}-rabbit immunoglobulin (Dakopatts; E0432; 1:200 dilution in TBS) was applied for 45 min as a bridging antibody, followed by a 45-min incubation with peroxidase-labeled streptavidin (Dakopatts; P0379; 1:100 dilution in TBS). Staining of the sections was performed by incubation in 0.1 M acetate buffer (pH 5.0) containing 0.03% 3-amino-9-ethylcarbazole and 0.03% H2O2 for 10 min, resulting in a red staining product. Finally, sections were counterstained in Mayer’s hematoxylin and mounted in Aquamount. As negative controls, TBS and preimmune serum were used instead of the primary antibody. The slides were independently evaluated by two readers, blinded to the other SOD assessments, to give a descriptive analysis.

Statistical Analyses.
The significance of the differences in the SOD antigen and activity levels, expressed in mean ± SE, between pairs of normal mucosa and carcinoma were evaluated using the paired Student’s t test. For comparison of data from different patient and sample groups, ANOVA and the unpaired Student’s t test were used; estimates for equality of variances showed no significant differences according to Levene’s F-test. For the statistical survival analyses of the group of gastric cancer patients, the clinicopathological parameters were dichotomized as follows: gender into males versus females; age in years into <66.2 versus >=66.2; TNM stage in stage I/II versus stage III/IV; Laurén classification in diffuse/mixed versus intestinal; WHO classification in differentiated (papillary, tubular, mucinous, and adenosquamous) versus undifferentiated (signet cell and undifferentiated); tumor localization in antrum versus corpus, fundus, and cardia; diameter of the tumor into <5 cm versus >=5 cm; number of eosinophils in many versus few/moderate; and intestinal metaplasia in normal mucosa in present versus absent. The optimal cutoff points of the age, diameter, and the SOD parameters in carcinoma and normal mucosa were assessed by slowly increasing the level until the point of best discrimination, i.e., optimal dichotomization. For age and diameter, no such point was found, and therefore, the median and 5 cm were used, respectively, to obtain comparable groups.

Univariate survival analysis was performed with the Cox proportional hazard model (25) , using the SPSS 6.0 statistical software package (SPSS, Inc., Chicago IL), resulting in the identification of covariates that significantly correlated with the overall survival of the patients. Multivariate survival analyses were performed using the Cox proportional hazards method by separately adding the significant SOD variables to the nine dichotomized clinicopathological parameters (i.e., gender and age of the patients, TNM stage, Laurén classification, WHO classification, localization, diameter, number of eosinophils of the tumors, and intestinal metaplasia of the normal mucosa). Overall survival curves were constructed using the method of Kaplan and Meier (26) . The statistical significance of the difference in survival of the groups was calculated using the log-rank test. Differences were considered significant when P <= 0.05.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Mn-SOD and Cu/Zn-SOD Concentrations.
The mean Mn-SOD and Cu/Zn-SOD concentrations as determined by ELISA are shown in Table 1Citation . The Mn-SOD content of both the gastric and esophageal carcinomas was significantly (P < 0.0005 and P = 0.007, respectively) higher compared with that of corresponding normal mucosa. Paired evaluation revealed that a large majority of the carcinomas had higher Mn-SOD levels than the normal tissue, i.e., 78% (63 of 81) of the gastric and 90% (9 of 10) of the esophageal tumors. In contrast, both carcinoma types contained less Cu/Zn-SOD antigen compared with their corresponding normal mucosa (P = 0.001 and P = 0.08, respectively).


View this table:
[in this window]
[in a new window]
  		Table 1 Mn-SOD and Cu/Zn-SOD antigen levels (ng/mg of protein) in normal mucosa and carcinomas of patients with gastric or esophageal cancera

 
The Mn-SOD and Cu/Zn-SOD content of the normal mucosa and carcinomas of the gastric cancer patients was also evaluated in relation to 10 dichotomized clinicopathological parameters, as shown in Table 2Citation . There were no significant differences in the Mn-SOD and Cu/Zn-SOD concentration between patients who were still alive and those who had died at the end of the follow-up. With regard to the other clinicopathological parameters, there was only a minor relation between Mn-SOD and gender of the patients, i.e., males contained less Mn-SOD in their normal mucosa compared with females. No other relevant associations between SOD levels and patient- or tumor-related features were observed.


View this table:
[in this window]
[in a new window]
  		Table 2 Mn-SOD and Cu/Zn-SOD antigen level (ng/mg of protein) in normal gastric mucosa and gastric carcinoma (n = 81), dichotomized according to various clinicopathological parametersa

 
SOD Activity.
The SOD activity levels were determined in 15 gastric normal mucosa-carcinoma pairs. There were no significant differences in the Mn-SOD and Cu/Zn-SOD activity levels, expressed as units/mg of protein, between normal gastric mucosa (4.5 ± 0.4 and 3.9 ± 0.5, respectively) and carcinomas (4.7 ± 0.6 and 3.8 ± 0.4, respectively). The Pearson’s correlation coefficient between the antigen and activity levels of Mn-SOD in these pairs was highly significant (overall r = 0.65, P < 0.0005; normal mucosa r = 0.84 and carcinoma r = 0.66), whereas for Cu/Zn-SOD, this linear correlation was only marginally significant (overall r = 0.36, P = 0.05; normal mucosa r = 0.33 and carcinoma r = 0.44). The corresponding protein levels, however, did show an increase of the Mn-SOD isoform from 509 ± 64 to 861 ± 133 (P = 0.01) and a nonsignificant (P = 0.08) decrease of the Cu/Zn-SOD isoform from 612 ± 38 to 479 ± 56 ng/mg of protein, respectively.

Immunohistochemistry.
In normal gastric mucosa, Mn-SOD was predominantly localized in the cytoplasm of the parietal cells, showing a granular staining pattern. Also, the mucous cells at the outer top of the foveolar epithelium contained Mn-SOD in their cytoplasm, whereas the other foveolar and glandular cells were negative or weakly positive (Fig. 1Citation A). The tumor cells within the gastric adenocarcinoma showed a relatively strong Mn-SOD immunoreactivity as compared with their normal epithelial counterparts (Fig. 1Citation B). Both in the normal mucosa and carcinoma tissue, most stromal cells (myofibroblasts and macrophages) only showed a weak to moderate Mn-SOD immunoreactivity.



View larger version (207K):
[in this window]
[in a new window]
  		Fig. 1. Immunohistochemical staining of gastric tissue for Mn-SOD (A and B) and Cu/Zn-SOD (C and D). The granular cytoplasmic staining of Mn-SOD is predominantly present in the parietal cells (black arrow) of the normal mucosa (A) and more intensely expressed in the gastric carcinoma cells (B). Cu/Zn-SOD was found to be diffusely expressed in the cytoplasm and nucleus of parietal cells (black arrow) within the normal mucosa (C) and only at a low level in the carcinomas (D). x200.

 
The Mn-SOD expression of the esophagus was mainly confined to the luminal site of the normal squamous epithelium, whereas in the carcinoma tissue, most tumor and stromal cells were moderately to strongly positive (Fig. 2Citation , A and B).



View larger version (163K):
[in this window]
[in a new window]
  		Fig. 2. Immunohistochemical staining of esophageal tissue for Mn-SOD (A and B) and Cu/Zn-SOD (C and D). Mn-SOD was particularly expressed in the luminal part of normal squamous epithelium of the esophagus (A) and was prominently present within the squamous cell carcinomas (B). In contrast, Cu/Zn-SOD was most strongly expressed in the cells of the deepest part of the basal layer in normal esophageal mucosa (C) and only marginally expressed in the carcinomas (D). x200.

 
Cu/Zn-SOD was found to be localized diffusely in the cytoplasm of the glandular cells of the normal gastric epithelium. Parietal cells showed cytoplasmic and/or nuclear Cu/Zn-SOD immunoreactivity (Fig. 1Citation C). Although Cu/Zn-SOD was found in the cytoplasm and/or nucleus of some tumor cells, most gastric carcinoma showed a less intense Cu/Zn-SOD immunoreactivity as compared with normal mucosa. Stromal cells in the normal mucosa and carcinoma were negative for Cu/Zn-SOD (Fig. 1Citation D). Concerning normal esophageal epithelium, the majority showed a strong cytoplasmic and/or nuclear staining of the deepest part of the basal layer, whereas the other cells only showed a weak to moderately cytoplasmic Cu/Zn-SOD immunoreactivity (Fig. 2Citation C). The tumor cells of the esophageal carcinoma were either negative or positive showing a very weak staining intensity of the cytoplasm and/or the nucleus (Fig. 2Citation D). Foci of negative and positive tumor cells were present within the same section. Stromal cells both in normal and carcinoma tissue were mainly negative.

Intestinal metaplasia, characterized by the presence of goblet cells, was sometimes found in the normal gastric mucosa. These metaplastic parts were strongly positive for both Mn-SOD and Cu/Zn-SOD, with negative goblet vacuoles (data not shown).

Survival Analyses of the Gastric Carcinoma Patients.
Sixty-six patients with a gastric carcinoma (81.5%; 19 females and 47 males) had died during follow-up, with a median survival time of 11.5 months (range, 0.5–74 months). Only 15 (18.5%; 2 females and 13 males) were still alive at the end of the study, with a median follow-up time of 50 months (range, 33–118 months). The patients who had died were slightly older (66.3 ± 1.4 years) compared with those still alive (63.9 ± 4.1). Furthermore, there was a decreased survival of the patients with TNM stage III or IV (15.6%) compared with TNM stage I or II patients (20.4%).

Univariate Cox survival analysis of the dichotomized clinicopathological parameters showed that several had some association with a poor survival; for example, female sex (survival, 9.5% versus 21.7% for males) and a large tumor diameter (survival, 14.7% versus 21.3% for small tumors), but only a high number of eosinophils within the carcinoma (survival, 0% versus 19.7% with low eosinophil numbers) and the absence of intestinal metaplasia of the normal mucosa (survival, 10.3% versus 26.2% of those with metaplasia) were significant (0.02 <= P <= 0.05) predictors of a poor overall survival. In the multivariate analysis, only the number of eosinophils of the tumor remained significantly associated with the overall survival (hazard ratio, 0.4; 95% confidence interval, 0.2–0.9; P = 0.03). Gender and age of the patients, TNM stage, Laurén classification, WHO classification, localization, and diameter of the tumor were found not to be significantly associated with the overall survival of the patients.

Optimal dichotomization of the antigen concentration in the carcinomas revealed that a high Mn-SOD content (>450 ng/mg of protein) was associated with a relatively poor overall survival of the patients (Table 3Citation ; Fig. 3Citation A). In contrast, a cutoff point could also be identified in the normal mucosa, at 335 ng/mg of protein Mn-SOD, which indicated that a low SOD level of the normal mucosa was associated with a relatively poor survival of the patients (Table 3Citation ; Fig. 3Citation B). Because of this diametrical observation, we additionally assessed whether the carcinoma:normal mucosa ratio of the Mn-SOD concentration within the patients was related to the survival as well. At a ratio >2.03, the survival was found to be significantly lower than below this ratio (Table 3Citation ; Fig. 3Citation C).


View this table:
[in this window]
[in a new window]
  		Table 3 Univariate and multivariate analysis of the dichotomized Mn-SOD parameters of carcinomas and normal mucosa in relation to the overall survival of patients with gastric cancera

 


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 3. Overall survival curves of patients with gastric cancer according to the Mn-SOD levels within the carcinomas (A), normal gastric mucosa (B), and the carcinoma:normal mucosa ratio of the Mn-SOD concentration (C). Values indicate the cutoff points of the Mn-SOD parameters and the number of patients alive/deceased at the end of the follow-up. Ps are according to the log-rank test. The numbers below indicate the patients remaining in the study at the corresponding observation time points. ····, the minimal follow-up of the patients at 33 months.

 
Multivariate analysis, in which the dichotomized SOD variables were adjusted to the assessed nine clinicopathological parameters, revealed that the carcinoma:normal mucosa Mn-SOD ratio remained significantly associated (P = 0.03) with a relatively poor overall survival of the patients, indicating its independent prognostic value. In these multivariate analyses, a high eosinophil content of the carcinomas and the absence of intestinal metaplasia in the normal gastric mucosa were consistently found to be significantly associated with the overall survival (0.4 < hazard ratio < 0.6; 95% confidence interval, 0.2–1.0; 0.03 < P <= 0.05).


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we showed that gastric adenocarcinomas and esophageal squamous cell carcinomas are characterized by a significantly increased expression of Mn-SOD. These results are in agreement with studies by Izutani et al. (18 , 19) who previously reported a greatly enhanced expression of Mn-SOD, at both the mRNA and protein level, in the same type of cancers, and with our report on SOD in the colorectal cancer sequence (16) . Moreover, the present study indicates that also in gastric cancer, the Mn-SOD level is of prognostic significance for the overall survival of the patients, similar to that as reported for colorectal cancer (17) .

In most cancer cells, there is an imbalance of antioxidant enzymes, as recently reviewed by Oberley and Oberley (27) . Although originally, SOD levels were thought to be lower in malignant cells and (experimental animal) tumors, when compared with normal nonmalignant cells and tissues (11 , 27 , 28) , several investigators challenged the concept that low (Mn-)SOD levels are a general feature of human neoplasia. For example, Beño et al. (29) showed that the antioxidant activity levels, including SOD, were increased in the gastric mucosa of patients at increased risk of gastric cancer. Also, colorectal carcinomas (30) and renal adenocarcinomas (31) were reported to have increased (Mn-)SOD activity levels. In addition, human tumors of the skin, ovary, brain, lung, and kidney have been reported to contain elevated Mn-SOD antigen levels, assessed either immunohistochemically or by ELISA of serum samples or tissue homogenates (32, 33, 34, 35, 36, 37) . The exact cause of the higher levels in tumor cells is not clear yet, but because Mn-SOD is an inducible enzyme (38 , 39) , it is possible that elevated levels of ROMs (40 , 41) or cytokines (42, 43, 44, 45) in the neoplastic tissue are responsible for its up-regulation. Moreover, in vitro studies have indicated that transfection of the Mn-SOD gene inhibits cell proliferation (46 , 47) , which even led to the assumption that this enzyme is antioncogenic. In this context, the increased Mn-SOD level might also be an adaptive response of the body to try to control tumor cell proliferation and the oncogenic process.

Whereas the Mn-SOD content was increased, the Cu/Zn-SOD content of gastric and esophageal carcinomas was decreased compared with the normal mucosa. In contrast to differences in the antigen level, carcinomas and normal mucosa showed comparable SOD activity levels, an observation similar to that in colorectal cancer (16) . This discrepancy between the SOD antigen and activity levels is thought to be attributable to endogenous inhibitors of the SOD enzymes (32) , to interferences in the enzymatic activity assay (48 , 49) , and to the contribution of the third isoform of SOD, i.e., extracellularly localized SOD, in the activity assessment.

Immunohistochemical analysis of normal gastric mucosa revealed that the SOD expression was relatively low, except for the metabolically active acid-producing parietal cells. Normal esophageal epithelium was characterized by the distinct localization of Mn-SOD in the luminal part and that of Cu/Zn-SOD in the basal proliferating part, which may be indicative of a differential function of each SOD isotype within this tissue. In the gastric and esophageal carcinomas, the Mn-SOD was strongly expressed in both the malignant tumor cells and in the stromal cells, which might indicate a high physiological activity of these cells. These findings also confirm the results of the ELISA measurements and concur with similar assessments as reported by Izutani et al. (18 , 19) . The expression of Cu/Zn-SOD in the gastric and esophageal carcinomas, which was confined to the tumor cells, was less evident compared with normal tissues.

To assess their clinical relevance, the Mn-SOD and Cu/Zn-SOD content of the normal gastric mucosa and carcinomas was evaluated in relation to the major clinicopathological parameters. There was only a minor relation between Mn-SOD and gender of the patients, whereas no other relevant associations were observed. This indicates that the SOD expression is independent from patient- and tumor-related factors, which are important characteristics of a putative prognostic factor. In the evaluation of the prognostic value of the SOD levels, univariate analyses revealed that a high Mn-SOD content of the carcinomas and a low Mn-SOD content of the normal mucosa were significantly associated with a relatively poor survival of the patients. Consequently, a high carcinoma:normal mucosa ratio of the Mn-SOD content was also significantly related to a poor survival. Our previous study concerning colorectal cancer patients showed similar results, i.e., a high Mn-SOD level of carcinomas was associated with a relatively poor survival of the patients (17) . The stage of the tumor is considered to be an important determinant of the prognosis of patients with gastric cancer (50, 51, 52, 53, 54, 55) . However, recognition of additional prognostic factors independent from the classic parameters could be of clinical significance (56, 57, 58, 59, 60, 61) . Adjusting the separate Mn-SOD variables to the clinicopathological parameters in the multivariate analysis revealed that a high carcinoma:normal mucosa Mn-SOD ratio remained significantly and independently associated with a relatively poor overall survival.

The exact underlying biological mechanism of this paradoxical and diametrical association is unknown, but the (dis)balance between ROM production and antioxidant defenses seems to be the most important (patho)physiological factor. Taking this into account, a relatively high Mn-SOD content of the carcinomas could stimulate the growth of the tumor cells by protecting them against high toxic ROMs concentrations, while maintaining a sufficient metabolically active oxygen signal to activate growth pathways. Indeed, it has been shown that low concentrations of ROMs can stimulate cell growth in vitro (62, 63, 64, 65) , induce the expression of some proto-oncogenes, e.g., c-fos and c-myc, and switch on DNA synthesis (62 , 64 , 66) . In addition, recent in vitro studies indicated that transfection of the Mn-SOD gene into cancer cells results in interference in the activity of several transcription factors and modulates cytokine- and chemotherapeutic agent-induced processes, such as apoptosis, cell transformation, and proliferation (67 , 68) . Furthermore, a high Mn-SOD content could protect tumor cells against the lethal effect of several anticancer therapies, which exert at least part of their anticarcinogenic effect by producing high concentrations of ROMs (11, 12, 13, 14) . Only six of our patients received additional (adjuvant) therapy, consisting of chemotherapy (four patients) and radiotherapy (two patients), but they did not differ from those who had not received an additional therapy with respect to the SOD levels and overall survival.

In the normal mucosa, a relatively low Mn-SOD content was found to be associated with a poorer survival of the patients. This low SOD content may provide an insufficient protection against the carcinogenic effect of ROMs, which are known to play a role at all stages of tumorigenesis (3 , 6, 7, 8, 9, 10 , 69) . Dreher et al. (70) proposed that whereas low ROM levels can stimulate cell division and promote tumor growth, intermediate levels of oxidative stress are most effective in cancer initiation. Perhaps in the normal mucosa, a low Mn-SOD content could result in these intermediate, carcinogenic levels of oxidative stress. In that respect, it is relevant to mention that our group previously showed that Helicobacter pylori-related gastritis, which is recognized as an important pathogenic factor in gastric carcinogenesis (71) , is also associated with an increased Mn-SOD level and with a slight decrease in Cu/Zn-SOD in the gastric mucosa (24) . In addition, successful H. pylori eradication resulted in a normalization of the (Mn-)SOD levels (72) . Others have shown that H. pylori infection is accompanied by a high production of ROMs by attracted and activated phagocytes, and this is considered to be one of the major causes of the mucosal damage (73 , 74) . Furthermore, because H. pylori infection is also associated with increased oxidative DNA damage in human gastric mucosa (75 , 76) , a high production of ROMs in H. pylori-infected gastric mucosa might play an important role in transforming the chronic gastritis into gastric carcinoma. A relatively high Mn-SOD level can thus be regarded as a defensive response by the host to protect the gastric mucosa against high, toxic ROMs concentrations. An inadequate or relatively low Mn-SOD level might render the normal gastric mucosa more vulnerable to oxidative stress and prone to tumor development, and it is apparently indicative of a poor clinical outcome of the patient.

Finally, the above described association between the Mn-SOD level and clinical outcome of patients with gastrointestinal cancer might also be genetically determined. This hypothesis is corroborated by the report of Ambrosone et al. (77) , who showed that the recently discovered genetic polymorphism in the mitochondrial targeting sequence of Mn-SOD is associated with an increased risk for the development of breast cancer. Further studies will have to elucidate whether the genetic variability of Mn-SOD affects the expression and activity of the enzyme and is related to the susceptibility of patients to develop (gastrointestinal) cancer.

In conclusion, esophageal and gastric carcinomas are characterized by an increased Mn-SOD antigen level compared with their corresponding normal tissue, similar to that previously shown for colorectal carcinomas. In contrast, the Cu/Zn-SOD content of esophageal and gastric carcinomas was decreased. Furthermore, a high carcinoma:normal mucosa Mn-SOD ratio in gastric cancer patients is associated with a relatively poor overall survival, which is independent from nine clinicopathological parameters. This ratio could thus be used as an independent prognostic parameter to predict the clinical outcome of patients with gastric cancer, which might enable better treatment planning.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by a grant of the Dutch Cancer Society (NKB-KWF RUL 94-864). Back

2 To whom requests for reprints should be addressed, at Department of Gastroenterology and Hepatology, Leiden University Medical Center, Building 1 C4-P, P. O. Box 9600, 2300 RC Leiden, the Netherlands. Phone: 31-715262680; Fax: 31-715248115; E-mail: H.W.Verspaget{at}LUMC.NL Back

3 The abbreviations used are: SOD, superoxide dismutase; ROM, reactive oxygen metabolite; Mn-SOD, manganese SOD; Cu/Zn-SOD, copper/zinc SOD; hr, human recombinant; TBS, Tris-buffered saline. Back

Received 12/ 1/99; revised 3/17/00; accepted 4/28/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. McCord J. M., Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem., 244: 6049-6055, 1969.[Abstract/Free Full Text]
  2. Fridovich I. Superoxide dismutases. Annu. Rev. Biochem., 44: 147-159, 1975.[CrossRef][Medline]
  3. Farber J. L., Kyle M. E., Coleman J. B. Biology of disease. Mechanisms of cell injury by activated oxygen species. Lab. Invest., 62: 670-679, 1990.[Medline]
  4. Beyer W., Imlay J., Fridovich I. Superoxide dismutases. Prog. Nucleic Acid Res. Mol. Biol., 40: 221-253, 1991.[Medline]
  5. Sahu S. C. Role of oxygen free radicals in the molecular mechanisms of carcinogenesis: a review. J. Environ. Sci. Health, C9: 83-112, 1991.
  6. Slater T. F. Free-radical mechanisms in tissue injury. Biochem. J., 222: 1-15, 1984.[Medline]
  7. Borek C. Radiation and chemically induced transformation: free radicals, antioxidants and cancer. Br. J Cancer, 55(Suppl.8): 74-86, 1987.
  8. Guyton K. Z., Kensler T. W. Oxidative mechanisms in carcinogenesis. Br. Med. Bull., 49: 523-544, 1993.[Abstract/Free Full Text]
  9. Farber J. L. Mechanisms of cell injury by activated oxygen species. Environ. Health Perspect., 102(Suppl.10): 17-24, 1994.
  10. Wiseman H., Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J., 313: 17-29, 1996.
  11. Oberley L. W., Buettner G. R. Role of superoxide dismutase in cancer: a review. Cancer Res., 39: 1141-1149, 1979.[Abstract/Free Full Text]
  12. Petkau A. Role of superoxide dismutase in modification of radiation injury. Br. J. Cancer, 55(Suppl.8): 87-95, 1987.
  13. Oberley L. Free radical biology: a paradox in cancer research. J. Natl. Cancer Inst., 82: 902-903, 1990.[Free Full Text]
  14. Sangeetha P., Das U. N., Koratkar R., Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic. Biol. Med., 8: 15-19, 1990.[CrossRef][Medline]
  15. Oury T. D., Chang L-I., Marklund S. L., Day B. J., Crapo J. D. Immunocytochemical localization of extracellular superoxide dismutase in human lung. Lab. Invest., 70: 889-898, 1994.[Medline]
  16. Janssen A. M. L., Bosman C. B., Kruidenier L., Griffioen G., Lamers C. B. H. W., van Krieken J. H. J. M., van de Velde C. J. H., Verspaget H. W. Superoxide dismutases in the human colorectal cancer sequence. J. Cancer Res. Clin. Oncol., 125: 327-335, 1999.[CrossRef][Medline]
  17. Janssen A. M. L., Bosman C. B., Sier C. F. M., Griffioen G., Kubben F. J. G. M., Lamers C. B. H. W., van Krieken J. H. J. M., van de Velde C. J. H., Verspaget H. W. Superoxide dismutases in relation to the overall survival of colorectal cancer patients. Br. J. Cancer, 78: 1051-1057, 1998.[Medline]
  18. Izutani R., Katoh M., Asano S., Ohyanagi H., Hirose K. Enhanced expression of manganese superoxide dismutase mRNA and increased TNF{alpha} mRNA expression by gastric mucosa in gastric cancer. World J. Surg., 20: 228-233, 1996.[CrossRef][Medline]
  19. Izutani R., Asano S., Imano M., Kuroda D., Kato M., Ohyanagi H. Expression of manganese superoxide dismutase in esophageal and gastric cancers. J. Gastroenterol., 33: 816-822, 1998.[CrossRef][Medline]
  20. Hermanek P., Sobin L. H. UICC TNM Classification of Malignant TumorsEd Springer 4. London 1992.
  21. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand., 64: 31-49, 1965.[Medline]
  22. Mulder, T. P. J., Verspaget, H. W., Janssens, A. R, de Bruin, P. A. F., Griffioen, G., and Lamers, C. B. H. W. Neoplasia related changes of two copper (Cu)/zinc (Zn) proteins in the human colon. Free Radic. Biol. Med., 10: 501–506, 1990.
  23. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.[Free Full Text]
  24. Götz J. M., van Kan C. I., Verspaget H. W., Biemond I., Lamers C. B. H. W., Veenendaal R. A. Gastric mucosal superoxide dismutases in Helicobacter pylori infection. Gut, 38: 502-506, 1996.[Abstract/Free Full Text]
  25. Cox D. R. Regression models and life-tables. Mathematics: Journal of the Royal Statistical Society, 34: 187-220, 1972.
  26. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.[CrossRef]
  27. Oberley T. D., Oberley L. W. Antioxidant enzyme levels in cancer. Histol. Histopathol., 12: 525-535, 1997.[Medline]
  28. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic. Biol. Med., 8: 583-599, 1990.[CrossRef][Medline]
  29. Beño I., Staruchová M., Volkovová K., Bátovsky M. Increased antioxidant enzyme activities in the colorectal adenoma and carcinoma. Neoplasma, 42: 265-269, 1995.[Medline]
  30. Satomi A., Murakami S., Hashimoto T., Ishida K., Matsuki M., Sonoda M. Significance of superoxide dismutase (SOD) in human colorectal cancer tissue: correlation with malignant intensity. J. Gastroenterol., 30: 177-182, 1995.[CrossRef][Medline]
  31. Yang A. H., Oberley T. D., Oberley L. W., Schmid S. M., Cummings K. B. In vitro modulation of antioxidant enzymes in normal and malignant renal epithelium. In Vitro Cell. Dev. Biol., 23: 546-558, 1987.[Medline]
  32. Iizuka S., Taniguchi N., Makita A. Enzyme-linked immunosorbent assay for human manganese-containing superoxide dismutase and its content in lung cancer. J. Natl. Cancer Inst., 72: 1043-1049, 1984.
  33. Ishikawa M., Yaginuma Y., Hayashi H., Shimizu T., Endo Y., Taniguchi N. Reactivity of a monoclonal antibody to manganese superoxide dismutase with human ovarian carcinoma. Cancer Res., 50: 2538-2542, 1990.[Abstract/Free Full Text]
  34. Oberley T. D., Sempf J. M., Oberley M. J., McCormick M. L., Muse K. E., Oberley L. W. Immunogold analysis of antioxidant enzymes in human renal cell carcinoma. Virchows Arch., 424: 155-164, 1994.[Medline]
  35. Schadendorf D., Zuberbier T., Diehl S., Schadendorf C., Czarnetzki B. M. Serum manganese superoxide dismutase is a new tumor marker for malignant melanoma. Melanoma Res., 5: 351-353, 1995.[Medline]
  36. Landriscina M., Remiddi F., Ria F., Palazzotti B., De Leo M. E., Iacoangeli M., Rosselli R., Scerrati M., Galeotti T. The level of MnSOD is directly correlated with grade of brain tumours of neuroepithelial origin. Br. J. Cancer, 74: 1877-1885, 1996.[Medline]
  37. Coursin D. B., Cihla H. P., Sempf J., Oberley T. D., Oberley L. W. An immunohistochemical analysis of antioxidant and glutathione S-transferase enzyme levels in normal and neoplastic human lung. Histol. Histopathol., 11: 851-860, 1997.
  38. Hassan H. M. Biosynthesis and regulation of superoxide dismutases. Free Radic. Biol. Med., 5: 377-385, 1988.[CrossRef][Medline]
  39. Touati D. Molecular genetics of superoxide dismutases. Free Radic. Biol. Med., 5: 393-402, 1988.[CrossRef][Medline]
  40. Qureshi A., Gorey T. F., Byrne P., Kay E., McKeever J., Hennessy T. P. J. Oxygen free radical activity in experimental colonic carcinoma. Br. J. Surg., 81: 1058-1059, 1994.[Medline]
  41. Warner B. B., Stuart L., Gebb S., Wispé J. R. Redox regulation of manganese superoxide dismutase. Am. J. Physiol., 271: L150-L158, 1996.[Abstract/Free Full Text]
  42. Wong G. H. W., Goeddel D. V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science (Washington DC), 242: 941-944, 1988.[Abstract/Free Full Text]
  43. Visner G. A., Dougall W. C., Wilson J. M., Burr I. A., Nick H. S. Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1, and tumor necrosis factor. Role in the acute inflammatory response. J. Biol. Chem., 265: 2856-2864, 1990.[Abstract/Free Full Text]
  44. Valentine J. F., Nick H. S. Acute-phase induction of manganese superoxide dismutase in intestinal epithelial cell lines. Gastroenterology, 103: 905-912, 1992.[Medline]
  45. Yoshimi N., Sato S., Makita H., Wang A., Hirose Y., Tanaka T., Mori H. Expression of cytokines, TNF-{alpha} and IL-1{alpha}, in MAM acetate and 1-hydroxyanthraquinone-induced colon carcinogenesis of rats. Carcinogenesis (Lond.), 15: 783-785, 1994.[Abstract/Free Full Text]
  46. St. Clair D. K., Oberley T. D., Muse K. E., St. Clair W. H. Expression of manganese superoxide dismutase promotes cellular differentiation. Free Radic. Biol. Med., 16: 275-282, 1994.[CrossRef][Medline]
  47. Kiningham K. K., St. Clair D. K. Overexpression of manganese superoxide dismutase selectively modulates the activity of jun-associated transcription factors in fibrosarcoma cells. Cancer Res., 57: 5265-5271, 1997.[Abstract/Free Full Text]
  48. Beyer J. F., Jr., Fridovich I. Assaying for superoxide dismutase activity: some large consequences of minor changes in conditions. Anal. Biochem., 161: 559-566, 1987.[CrossRef][Medline]
  49. Weber G. F. The measurement of oxygen-derived free radicals and related substances in medicine. J. Clin. Chem. Clin. Biochem., 28: 569-603, 1990.[Medline]
  50. Allum W. H., Powell D. J., McConkey C. C., Fielding J. W. L. Gastric cancer: a 25-year review. Br. J. Surg., 76: 535-540, 1989.[Medline]
  51. Rohde H., Gebbensleben B., Bauer P., Stützer H., Zieschang J. Has there been any improvement in the staging of gastric cancer. Cancer (Phila.), 64: 2465-2481, 1989.[CrossRef][Medline]
  52. Nakamura K., Ueyama T., Yao T., Xuan Z. X., Ambe K., Adachi Y., Yakeishi Y., Matsukuma A., Enjoji M. Pathology and prognosis of gastric carcinoma. Cancer (Phila.), 70: 1030-1037, 1992.[CrossRef][Medline]
  53. Roder J. D., Böttcher K., Siewert J. R., Busch R., Hermanek P., Meyer H. J. Prognostic factors in gastric carcinoma. Cancer (Phila.), 72: 2089-2097, 1993.[CrossRef][Medline]
  54. Fuch C. S., Mayer R. J. Gastric carcinoma. N. Engl. J. Med., 333: 32-41, 1995.[Free Full Text]
  55. Kwon S. J., Kim G. S. Prognostic significance of lymph node metastasis in advanced carcinoma of the stomach. Br. J. Surg., 83: 1600-1603, 1996.[Medline]
  56. Iwasaki K., Torisu M., Fujimura T. Malignant tumor and eosinophils. I. Prognostic significance in gastric cancer. Cancer (Phila.), 58: 1321-1327, 1986.[CrossRef][Medline]
  57. Yu C. C. W., Levison D. A., Dunn J. A., Ward L. C., Demonakou M., Allum W. H., Hallisey M. T. Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. Br. J. Cancer, 71: 1106-1110, 1995.[Medline]
  58. Songun I., van de Velde C. J. H., Hermans J., Pals S. T., Verspaget H. W., Vis A. N., Menon A. G., Litvinov S. V., van Krieken J. H. J. M. Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Br. J. Cancer, 74: 1783-1788, 1996.[Medline]
  59. Pretlow T. P., Keith E. F., Cryar A. K., Bartolucci A. A., Pitts A. M., Pretlow T. G., Kimball P. M., Boohaker E. A. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res., 43: 2997-3000, 1983.[Abstract/Free Full Text]
  60. Ganesh S., Sier C. F. M., Heerding M. M., van Krieken J. H. J. M., Griffioen G., Welvaart K., van de Velde C. J. H., Verheijen J. H., Lamers C. B. H. W., Verspaget H. W. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer (Phila.), 77: 1035-1043, 1996.[CrossRef][Medline]
  61. Sier C. F. M., Kubben F. J. G. M., Ganesh S., Heerding M. M., Griffioen G., Hanemaaijer R., van Krieken J. H. J. M., Lamers C. B. H. W., Verspaget H. W. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer, 74: 413-417, 1996.[Medline]
  62. Shibanuma M., Kuroki T., Nose K. Induction of DNA replication and expression of proto-oncogene c-myc and c-fos in quiescent Balb/3T3 cells by xanthine/xanthine oxidase. Oncogene, 3: 17-21, 1988.
  63. Murrell G. A. C., Francis M. J. O., Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J., 265: 659-665, 1990.[Medline]
  64. Shibanuma M., Kuroki T., Nose K. Stimulation by hydrogen peroxide of DNA synthesis, competence family gene expression and phosphorylation of a specific protein in quiescent Balb/3T3 cells. Oncogene, 5: 1025-1032, 1990.[Medline]
  65. Burdon R. H., Gill V., Alliangana D. Hydrogen peroxide in relation to proliferation and apoptosis in BHK-21 hamster fibroblasts. Free Radic. Res., 24: 81-93, 1996.[Medline]
  66. Crawford D., Zbinden I., Amstad P., Cerutti P. Oxidant stress induces the proto-oncogenes c-fos and c-myc in mouse epidermal cells. Oncogene, 3: 27-32, 1988.
  67. Li J-J., Oberley L. W., Fan M., Colburn N. H. Inhibition of AP-1 and NF-{kappa}B by manganese-containing superoxide dismutase in human breast cancer cells. FASEB J., 12: 1713-1723, 1998.[Abstract/Free Full Text]
  68. Manna S. K., Zhang H. J., Yan T., Oberley L. W., Aggarwal B. B. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-{kappa}B and activated protein-1. J. Biol. Chem., 273: 13245-13524, 1998.[Abstract/Free Full Text]
  69. Cerutti P. A. Pro-oxidant states and tumor promotion. Science (Washington DC), 227: 375-381, 1985.[Abstract/Free Full Text]
  70. Dreher D., Junod A. F. Role of oxygen free radicals in cancer development. Eur. J. Cancer, 32A: 30-38, 1996.[CrossRef]
  71. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res., 52: 6735-6740, 1992.[Abstract/Free Full Text]
  72. Götz J. M., Thio J. L., Verspaget H. W., Offerhaus G. J. A., Biemond I., Lamers C. B. H. W., Veenendaal R. A. Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dimutases. Gut, 40: 591-596, 1997.[Abstract/Free Full Text]
  73. Mooney C., Keenan J., Munster D., Wilson I., Allardyce R., Bagshaw P., Chapman B., Chadwick V. Neutrophil activation by Helicobacter pylori. Gut, 32: 853-857, 1991.[Abstract/Free Full Text]
  74. Davies G. R., Simmonds N. J., Stevens T. R. J., Sheaff M. T., Banatvala N., Laurenson I. F., Blake D. R., Rampton D. S. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut, 35: 179-185, 1994.[Abstract/Free Full Text]
  75. Baik S-C., Youn H-S., Chung M-H., Lee W-K., Cho M-J., Ko G-H., Park C-K., Kasai H., Rhee K-H. Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Cancer Res., 56: 1279-1282, 1996.[Abstract/Free Full Text]
  76. Farinati F., Cardin R., Degan P., Rugge M., Di Mario F., Bonvicini P., Naccarato R. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut, 42: 351-356, 1998.[Abstract/Free Full Text]
  77. Ambrosone C. B., Freudenheim J. L., Thompson P. A., Bowman E., Vena J. E., Marshall J. R., Graham S., Laughlin R., Nemoto T., Shields P. G. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res., 59: 602-606, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
C. E. Whibley, K. L. McPhail, R. A. Keyzers, M. F. Maritz, V. D. Leaner, M. J. Birrer, M. T. Davies-Coleman, and D. T. Hendricks
Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinones
Mol. Cancer Ther., September 1, 2007; 6(9): 2535 - 2543.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. J. Murphy, A. E. Hughes, C. C. Patterson, L. A. Anderson, R.G.P. Watson, B. T. Johnston, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray
A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma
Carcinogenesis, June 1, 2007; 28(6): 1323 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
B. Hermann, Y. Li, M. B. Ray, J. M. Wo, and R. C. G. Martin II
Association of Manganese Superoxide Dismutase Expression With Progression of Carcinogenesis in Barrett Esophagus
Arch Surg, December 1, 2005; 140(12): 1204 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Hu, D. G. Rosen, Y. Zhou, L. Feng, G. Yang, J. Liu, and P. Huang
Mitochondrial Manganese-Superoxide Dismutase Expression in Ovarian Cancer: ROLE IN CELL PROLIFERATION AND RESPONSE TO OXIDATIVE STRESS
J. Biol. Chem., November 25, 2005; 280(47): 39485 - 39492.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. B. Ambrosone, J. Ahn, K. K. Singh, H. Rezaishiraz, H. Furberg, C. Sweeney, B. Coles, and A. Trovato
Polymorphisms in Genes Related to Oxidative Stress (MPO, MnSOD, CAT) and Survival After Treatment for Breast Cancer
Cancer Res., February 1, 2005; 65(3): 1105 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
V. L. Kinnula, T. Torkkeli, P. Kristo, R. Sormunen, Y. Soini, P. Paakko, T. Ollikainen, K. Kahlos, A. Hirvonen, and S. Knuutila
Ultrastructural and Chromosomal Studies on Manganese Superoxide Dismutase in Malignant Mesothelioma
Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2): 147 - 153.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. I. T. Sihvo, T. Ruohtula, M. I. Auvinen, A. Koivistoinen, A. L. Harjula, and J. A. Salo
Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus
J. Thorac. Cardiovasc. Surg., January 1, 2004; 126(6): 1952 - 1957.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G.-C. Hur, S. J. Cho, C.-H. Kim, M. K. Kim, S. I. Bae, S. Y. Nam, J.-W. Park, W. H. Kim, and B. L. Lee
Manganese Superoxide Dismutase Expression Correlates with Chemosensitivity in Human Gastric Cancer Cell Lines
Clin. Cancer Res., November 15, 2003; 9(15): 5768 - 5775.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. K. Nelson, A. C. Ranganathan, J. Mansouri, A. M. Rodriguez, K. M. Providence, J. L. Rutter, K. Pumiglia, J. A. Bennett, and J. A. Melendez
Elevated Sod2 Activity Augments Matrix Metalloproteinase Expression: Evidence for the Involvement of Endogenous Hydrogen Peroxide in Regulating Metastasis
Clin. Cancer Res., January 1, 2003; 9(1): 424 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. L. Janssen, W. van Duijn, F. J. G. M. Kubben, G. Griffioen, C. B. H. W. Lamers, J. H. J. M. van Krieken, C. J. H. van de Velde, and H. W. Verspaget
Prognostic Significance of Metallothionein in Human Gastrointestinal Cancer
Clin. Cancer Res., June 1, 2002; 8(6): 1889 - 1896.